AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28703859
Drug: Iron pills
RxNorm normalized name: iron carbonyl Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron pills
Trial: 23905375
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SFI) at 1.5 mL/kg (dissolved in 250 mL 5% glucose solution), administered intravenously once daily for 5 days before operation.
Trial: 23905375
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (control group), equal dose to SFI group, administered 30 min before anesthesia induction.
Trial: 21568982
Drug: i-gel (mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel (mild subgroup)
Trial: 21568982
Drug: i-gel (moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel (moderate subgroup)
Trial: 19123002
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m² on a 21-day schedule (group A)
Trial: 19123002
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m² on a 7-day schedule (group B)
Trial: 16820373
Drug: Tranilast 100
RxNorm normalized name: tranilast 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast 100 mg, 3 times daily (T(+) group)
Trial: 16820373
Drug: Tranilast treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast treatment vs Control
Trial: 15585141
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (40 mg or 0.01 ml/kg, subcutaneous injection, every 12 hours)
Trial: 11027423
Drug: 13-Cis retinoic
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-Cis retinoic acid at a dose of 0.75 mg/kg/day
Trial: 8436775
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg oral calcium
Trial: 29186389
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg orally twice daily for 10 days
Trial: 26994634
Drug: Supportive medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive medications (any)
Trial: 26994634
Drug: Non-opioid psychotropic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid psychotropic medications
Trial: 15764959
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg weekly for 48 weeks) + vitamin D (400 IU daily) + calcium (1000 mg daily)
Trial: 15764959
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (400 IU daily) + calcium (1000 mg daily)
Trial: 7850589
Drug: Ritodrine hydrochloride
RxNorm normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritodrine hydrochloride 10 mg by mouth
Trial: 7850589
Drug: Monitoring without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monitoring without treatment
Trial: 11191179
Drug: Flumazenil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 0.5 mg
Trial: 15456079
Drug: peginterferon alpha-2a
RxNorm normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alpha-2a 180 microg once weekly
Trial: 15456079
Drug: peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alpha-2b 1.0 microg/kg once weekly
Trial: 11373253
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of alcohol per day (as beer, red wine or spirits) for 6 weeks
Trial: 9170763
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) including detailed explanation of obsessive thoughts, exposure, response prevention, cognitive restructuring, and relapse prevention.
Trial: 8190534
Drug: High titer
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titer Edmonston-Zagreb measles vaccine
Trial: 8190534
Drug: Medium titer
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium titer Edmonston-Zagreb measles vaccine
Trial: 29189583
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training performed in different sessions (CT)
Trial: 24763755
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids administered within 2 to 3 days of antibiotic therapy
Trial: 24763755
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids administered after 4 or more days of antibiotic therapy
Trial: 24763755
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids administered earlier in patients with non-Nocardia keratitis
Trial: 24763755
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids administered earlier in patients with no topical antibiotic use before enrollment
Trial: 20097461
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (RAS inhibitors [ACE inhibitors plus ARBs] plus high‐dose statin and spironolactone)
Trial: 20097461
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (ACE inhibitors with low‐dose statin)
Trial: 18247193
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA, 1000 mg)
Trial: 18247193
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EPA and fluoxetine
Trial: 8701396
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFA) 3 g daily
Trial: 6430310
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (0.3 mg i.m. followed by 0.4 mg every 6 h for 3 days)
Trial: 6430310
Drug: Intermittent morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent morphine (10 mg i.m.)
Trial: 6430310
Drug: Intermittent morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent morphine
Trial: 31204885
Drug: Male contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Male contraceptive pill willingness
Trial: 17113190
Drug: Continuous etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous etanercept therapy (50 mg once weekly)
Trial: 17113190
Drug: Interrupted etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Interrupted etanercept therapy (50 mg once weekly)
Trial: 17113190
Drug: Interrupted etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Interrupted etanercept therapy
Trial: 12009350
Drug: Depot GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depot GnRH agonist followed by 17beta-estradiol transdermal patches (100 to 300 microg for at least 12 days)
Trial: 12009350
Drug: Endometrial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial preparation starting on day 1 of menstrual cycle with 200 microg increasing to 300 microg after 7 days
Trial: 3841228
Drug: Pirenzepine 10
RxNorm normalized name: pirenzepine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 10 mg
Trial: 7609299
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pirenzepine 10 mg and famotidine 20 mg
Trial: 326594
Drug: 0.05% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% betamethasone 17,21-dipropionate cream
Trial: 30519776
Drug: Vibrotactile feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrotactile feedback using a 'balance' belt worn around the waist for 1 month in daily life.
Trial: 22185726
Drug: Intravenous esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esmolol infusion
Trial: 8464394
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms nocloprost (solved in 50 cc water)
Trial: 24219814
Drug: Nebulized tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nebulized tobramycin 300 mg twice a day (TNS)
Trial: 24219814
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin (IV)
Trial: 21979491
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lactobacillus rhamnosus LPR and Bifidobacterium longum BL999) in Finnish infants
Trial: 21979491
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in Finnish infants
Trial: 21979491
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment in German infants
Trial: 18926162
Drug: 10% glucose/insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glucose/insulin infusion
Trial: 18926162
Drug: Intralipid plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid plus heparin infusion
Trial: 12360590
Drug: CPAP-therapy (REMstar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP-therapy (REMstar Choice, Respironics, USA)
Trial: 2101170
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release naproxen (750 mg/day for 10-15 days)
Trial: 2101170
Drug: Standard naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard naproxen (two 375 mg/day capsules for 10-15 days)
Trial: 28564557
Drug: Minocycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (100 mg orally twice daily)
Trial: 21848448
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type B (BTX‐B) injections on one side of the face
Trial: 21848448
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control injections on the other side of the face
Trial: 9144684
Drug: Paclitaxel (Taxol)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (Taxol) 175 mg/m2 followed by cisplatin 80 mg/m2
Trial: 9144684
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 followed by teniposide (Vumon) 100 mg/m2
Trial: 9316683
Drug: Nimodipine (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (90 mg q.d.)
Trial: 8494126
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg
Trial: 3234468
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg with Diazepam 10 mg
Trial: 28550377
Drug: Hydroxycellulose (HEC)
RxNorm normalized name: Hydroxycellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxycellulose (HEC) placebo gel
Trial: 27871242
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy for 12 months
Trial: 25183661
Drug: Methylphenidate modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate modified-release long-acting formulation (MPH-LA) at 20 mg/day, up-titrated to 40-80 mg/day
Trial: 25183661
Drug: Methylphenidate modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate modified-release long-acting formulation (MPH-LA)
Trial: 20808923
Drug: Amodiaquine &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine & Artesunate (AS+AQ) monthly
Trial: 17511193
Drug: KY gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KY gel
Trial: 16014845
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (DEC/ALB)
Trial: 10193779
Drug: TASP-V (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TASP-V (10 microg kg(‐1) intranasal pretreatment)
Trial: 10193779
Drug: TASP-V (1.275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TASP-V (1.275 microg kg(‐1) intranasal pretreatment)
Trial: 7738436
Drug: Colored overlays
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colored overlays or lenses (e.g., Irlen lenses)
Trial: 8095507
Drug: Nicardipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (30 mg three times daily)
Trial: 6107945
Drug: DL-308 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-308 (10 mg)
Trial: 6107945
Drug: DL-308 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-308 (20 mg)
Trial: 6107945
Drug: Thioridazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (50 mg)
Trial: 6107945
Drug: DL-308 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-308 (10 mg) vs Thioridazine (50 mg)
Trial: 6107945
Drug: DL-308 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-308 (10 mg) and Thioridazine (50 mg)
Trial: 28588793
Drug: L-Glutamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine (10 g orally three times daily)
Trial: 28588793
Drug: L-Glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine
Trial: 26109814
Drug: Autologous CD34(+)
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CD34(+) cell infusion
Trial: 26109814
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment for liver cirrhosis
Trial: 23063301
Drug: eszopiclone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eszopiclone (all doses)
Trial: 19242916
Drug: Restorative yoga
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restorative yoga (RY) intervention (10 weekly 75-minute classes)
Trial: 15007319
Drug: Intra-articular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular ketamine (0.5 mg/kg)
Trial: 11247525
Drug: Keys to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keys to Caregiving program delivered by 6-weekly visits
Trial: 11247525
Drug: Control program
RxNorm normalized name: ZO Skin Health Pigment Control Program Plus Hydroquinone KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control program consisting of 6-weekly neutral visits
Trial: 8021573
Drug: Felodipine 10-20
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 10-20 mg once daily for four weeks
Trial: 23740664
Drug: PDT +
RxNorm normalized name: Photodynamic Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT + surgery (4 sessions of topical PDT mediated with 20% 5-aminolevulinic acid)
Trial: 16117956
Drug: Daily visits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily visits for 1 month
Trial: 16117956
Drug: Weekly visits
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly visits
Trial: 9199724
Drug: Psychiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment based on a psychodynamic approach (PT)
Trial: 1391144
Drug: Cisapride 30
RxNorm normalized name: cisapride 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 30 mg/daily for two months
Trial: 1391144
Drug: Sucralfate 4
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate 4 g/daily for two months
Trial: 3900900
Drug: Hydralazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (2 mg/kg/day) for 3 days
Trial: 18032997
Drug: Vaginal lubricants
RxNorm normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal lubricants (2 types of gels, suppositories) in addition to male and female condoms
Trial: 3933197
Drug: NaCl infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaCl infusion (control group during crossover study)
Trial: 23792625
Drug: cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cTnT levels ≥0.01 ng/ml
Trial: 15314987
Drug: Ticlopidine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (125 mg twice every 24h)
Trial: 10229733
Drug: DCLHb (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb (25, 50, and 100 mg/kg doses over 72 hours)
Trial: 10229733
Drug: DCLHb (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb (100 mg/kg)
Trial: 17571284
Drug: Sitagliptin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 400 mg
Trial: 17571284
Drug: Sitagliptin 25-400
RxNorm normalized name: SITagliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 25-400 mg
Trial: 9707305
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg once daily for three days)
Trial: 9707305
Drug: Cefaclor (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (30 mg/kg divided into three daily doses for ten days)
Trial: 8585766
Drug: Acetaminophen (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (650 mg every 4 h)
Trial: 8585766
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 mg every 4 h)
Trial: 8585766
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg per day)
Trial: 8585766
Drug: Acetaminophen, Aspirin,
RxNorm normalized name: Acetaminophen, Aspirin, and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, Aspirin, and Prednisone (as a group)
Trial: 2242782
Drug: Topical human
RxNorm normalized name: thrombin topical human topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical human leukocyte alpha-interferon 10(6) IU/g
Trial: 2242782
Drug: Topical human
RxNorm normalized name: thrombin topical human topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical human leukocyte alpha-interferon 10(4) IU/g
Trial: 355958
Drug: Bromocriptine mesylate
RxNorm normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine mesylate (2.5 mg twice daily for 14 days postpartum)
Trial: 21729808
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion to maintain BG level between 110 mg/dL and 126 mg/dL during surgery
Trial: 6993163
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no insulin therapy)
Trial: 19458605
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg once daily
Trial: 14767445
Drug: Omalizumab (0.016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (0.016 mg/kg per IgE (IU/mL))
Trial: 11027921
Drug: Cocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (20 mg or 40 mg)
Trial: 27209269
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of renal replacement therapy (RRT) within 8 hours of diagnosis (n=112)
Trial: 27209269
Drug: Delayed initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed initiation of renal replacement therapy (RRT) within 12 hours of stage 3 AKI or no initiation (n=119)
Trial: 27373900
Drug: HPV 16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV 16/18 AS04-adjuvanted vaccine
Trial: 18054942
Drug: Pioglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone treatment (3 years)
Trial: 15630733
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg twice a week